News
Myeloid Therapeutics, a company developing in vivo cell therapies for cancer as well as a novel gene editing technology, has ...
Tariffs on pharmaceutical products that President Donald Trump has teased for weeks are one step closer to fruition after the ...
CDC vaccine advisors are set to meet this week after two-month delay and scrutiny from Kennedy
A panel of experts who decide the national immunization schedule will meet on Tuesday for the first time in 2025, providing ...
Duality Biologics, a Chinese antibody-drug conjugates startup, to go public on Hong Kong Stock Exchange with $194M IPO amid ...
AbbVie and Sandoz have resolved their patent dispute over AbbVie’s blockbuster immunology drug Rinvoq. Sandoz ...
The government is fighting in court for a plan to cut spending on overhead research costs for grantees. Primate centers fear ...
After accumulating $86 billion in global sales, Amgen is still trying to keep Enbrel biosimilars off the market, Sandoz ...
In a development landscape as extensive as obesity, we think Pfizer could be better served by looking outside,' Stifel ...
Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they ...
Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad ...
Tome Bio founders wrangle ‘jumping genes’ to create new programmable gene insertion tool
Scientists develop STITCHR, a retrotransposon-based gene editing tool, by Omar Abudayyeh (Mass General Brigham) and Jonathan ...
Under the 11-page 'roadmap' outlined Thursday, the goal is for animal testing to become 'the exception rather than the norm' ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results